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Abstract: The paper focuses on recent achievements in the search for new chemical 
compounds able to inhibit multidrug resistance (MDR) mechanisms in Gram-positive 
pathogens. An analysis of the results of the search for new efflux pump inhibitors (EPIs) 
for Gram-positive bacteria, which have been performed over the last decade, indicates that 
almost all efforts are focused on the NorA (MFS) efflux pump in S. aureus. Considering 
the chemical structures of the NorA EPIs that have been identified, it can be observed that 
the most active agents belong to the families of compounds possessing conjugated double 
bonds, e.g., chalcones, piperine-like compounds, N-cinnamoylphenalkylamides or citral 
amide derivatives. Indole-, dihydronaphthyl-, 2-chloro-5-bromo-phenyl- or piperidine 
moieties seem to be profitable for the EPI properties, as well. These results, together with 
an increasing knowledge about a variety of efflux pumps that are involved in MDR of 
Gram-positive pathogens underline that further search for new EPIs should pay more 
attention to develop MDR efflux protein targets, including SMR, MATE, ABC or other 
members of the MFS family. 
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1. Introduction  
As a consequence of the intense fight against infections, bacteria have evolved through numerous 
defenses against antimicrobial agents [1]. The main mechanisms whereby the bacteria develop 
resistance to antimicrobial agents include enzymatic inactivation [2,3], modification of the drug 
target(s) [3,4], and reduction of intracellular drug concentration by changes in membrane permeability [3,5] 
or by the overexpression of efflux pumps [3,6]. With respect to efflux pumps, they provide a self-defense 
mechanism by which antibiotics are actively removed from the cell. For antibacterials, this results in 
sublethal drug concentrations at the active site that in turn may predispose the organism to the 
development of high-level target-based resistance [3,7]. Therefore, efflux pumps are viable 
antibacterial targets and identification and development of potent efflux pump inhibitors is a promising 
and valid strategy [3,8] which can restore the susceptibility of resistant strains to antibacterial agents 
that are substrates of efflux pumps [3,9]. The combination of a resistance inhibitor with an antibiotic 
has already proven its efficacy with the clavulanic acid (inhibitor of beta-lactamase)/amoxicillin 
association [10]. Predominantly, the world search for new tools to combat multidrug resistance (MDR) 
among bacterial pathogens is concentrated on Gram-negative bacteria aspects [11–18] because of their 
more complicated MDR mechanisms due to their double-membrane cells, which allow the expression 
of a tripartite efflux pump system such as AcrA/AcrB/TolC in Enterobacteriaceae [19–21] or MexA/ 
MexB/OprM in Pseudomonas aeruginosa [22–24]. Although the 3D-structures of protein components 
of the tripartite efflux pumps have been identified experimentally [25], which should simplify studies 
on inhibitor-binding pockets, the knowledge about the pump-inhibitor interactions is still not sufficient 
to involve the “protein-ligand drug design” approach in the search for new EPIs for Gram-negative 
pathogens. Results of recent microbiological- and medicinal chemistry studies allowed us to identify 
several chemical families of compounds inhibiting tripartite MFP/RND/OMF pump action [12,13,16,25] 
but it is hard to find a good pharmacophore model resulting from the studies that could be applicable in 
further design of new potent EPIs. 
Indeed, various lines of evidence [1,3,10,26–38] have indicated a significant development of 
medicinal chemistry tools useful in the search for efflux pump inhibitors for Gram-positive pathogens. 
As multidrug resistant Gram-positive bacteria have been and still are a current therapeutic problem, it 
is of great importance to analyze the recent progress in the search for new tools to combat it. Thus, this 
paper focuses on recent achievements in the search for new chemical compounds able to inhibit MDR 
mechanisms in Gram-positive pathogens.  
2. Efflux Pumps in Gram Positive Bacteria 
Efflux pumps in Gram-positive bacteria belong to four unrelated families (Table 1): MFS (major 
facilitator superfamily), SMR (small multidrug resistance), ABC (ATP-binding cassette) and MATE 
(Multidrug And Toxic Compound Extrusion) [9,39–54].  
MFS transporters are typically composed of approx. 400 amino acids that are putatively arranged into 
12 membrane-spanning helices, with a large cytoplasmic loop between helices six and seven [39,55,56]. 
The examples of MFS efflux pumps in Gram-positive bacteria are NorA, NorB, MdeA, Tet38 
(Staphylococcus aureus), LmrB, Bmr, Bmr3, Blt (Bacillus subtilis), MefA (Streptococcus pyogenes), 
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MefE (Streptococcus pneumoniae) or CmlR (Streptococcus coelicor) [39,55,57–59]. SMR transporters 
consist of approx. 110 amino acids and contain four transmembrane helices.  
Table 1. Efflux pumps in Gram positive bacteria and their role in antibiotics transport. 
Bacterial strain 
Transport 
protein family 
Efflux pump Substrates 
Staphylococcus aureus
 
MFS [9,41–44] 
 
 
MATE [45] 
 
SMR [39,60,61] 
NorA 
NorB 
MdeA 
Tet38 
MepA 
Smr, QacG, QacH 
NOR, CPX 
NOR, CPX, SPX 
Macrolides 
tetracyclines 
FQ, glycylcyclines 
- 
Staphylococcus spp 
MFS [9,46,47]
 
ABC [47–49] 
Mef(A) 
MsrA 
Macrolides 
Macrolides, type B 
streptogramins 
Staphylococcus 
haemolyticus 
MFS [42] MdeA 
Macrolides, lincosamides 
type A streptogramins 
Staphylococcus lentus [54]
 
FexA - 
Streptomyces 
coelicolor 
MFS [38]
 
CmlR1, CmlR2 Chloramphenicol 
Streptomyces spp MFS [50]
 Cml, Cmlv, Cmr, Cmx, 
CmA 
- 
Streptococcus spp MFS [9,45,47]
 
Mef(A) Macrolides 
Streptococcus 
pneumoniae 
ABC [51]
 
MFS [52]
 
Msr(D) 
PmrA 
Macrolides, ketolides 
NOR, CPX 
Clostridium difficile 
MFS [53]
 
MATE [45]
 
Cme 
CdeA 
Erythromycin 
FQ 
Bacillus subtilis 
MFS [9,46]
 
 
LmrB 
Bmr, Bmr3, Blt 
Lincosamides 
FQ 
Bacillus glutamicum MFS [9,46]
 
LmrB Lincosamides 
NOR: norfloxacin; CPX: ciprofloxacin; SPX: sparfloxacin; FQ: flouroquinolones. 
Owing to the small sizes of the proteins that belong to this family, they probably function as 
oligomeric complexes [39,59]. The examples of SMR efflux pumps in Gram-positive bacteria are 
EbrAB (Bacillus subtilis) or Smr, QacG, QacH (Staphylococcus aureus) [39,60,61]. MATE efflux 
proteins consist of 400–700 amino acids that form 12 transmembrane helices. All proteins of the 
MATE family exhibit almost 40% identity of their amino acid sequence. All genes that encode MATE 
proteins are derived from the same gene which was subsequently duplicated. An example of MATE 
efflux pump in Gram-positive bacteria is MepA protein found in Staphylococcus aureus [62,63].  
MFS, SMR and MATE transporters use a transmembrane proton gradient as the driving force for 
transport [39,62–65]. The minimal structural organization of an ABC transporter includes the presence 
of four domains, i.e., two nucleotide binding domains (NBDs) and two transmembrane permease 
domains (TMDs). The TMDs usually consist of six transmembrane α-helices and form homo or 
heterodimers. Two NBDs bind ATP in the cytoplasmic side and cooperate with transmembrane 
domains [39,65,66]. 
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The feature which distinguishes ABC transporters from the remaining families is the energy source 
for active extrusion of drugs, as it comes from the hydrolysis of ATP. Binding and hydrolysis of ATP 
triggers conformational changes in the transporter’s structure, which enable export of substrates [39,67]. 
The examples of ABC efflux pumps in Gram-positive bacteria are LmrA (Lactococcus lactis) or 
Rv1217c–Rv1218c (Mycobacterium tuberculosis) [39,55,68]. 
Multidrug resistance efflux pumps are recognized as an important component of resistance in both 
Gram-positive and Gram-negative bacteria. Some bacterial efflux pumps may be selective for one 
substrate or transport antibiotics of different classes, conferring a multiple drug resistance (MDR) 
phenotype. Efflux pumps inhibitors (EPIs) are promising therapeutic agents, as they should restore the 
activity of standard antibiotics. The efflux pump inhibitor-antibiotic combination is expected to 
increase the intracellular concentration of antibiotics that are expelled by efflux pumps, decrease the 
intrinsic bacterial resistance to antibiotics, reverse the acquired resistance associated with efflux pumps 
overexpression, and reduce the frequency of the emergence of resistant mutant strains [69]. 
Bypassing efflux pump activity may be achieved through a variety of different approaches: (1) by 
modifying the chemical design of previous antibiotics to reduce their respective affinity for binding 
sites and cavities located inside the pump transporter; (2) by increasing the influx of antibiotics, using 
membrane permeabilizers that subsequently increase the intracellular concentration of drugs; (3) by 
down-regulating the expression of efflux pump genes and/or decreasing the level of active efflux 
complexes in the bacterial envelope; (4) by collapsing the energy required to support the drug 
transport; (5) by inhibiting the functional assembly of efflux pump components; (6) by inserting a 
carefully-designed molecular plug inside the membrane channels responsible of antibiotic transport 
(inside the pump cavities or inside the exit channel component) or (7) by generating a dynamic 
competition, between a decoy- substrate and the antibiotic, during transport flux inside the pump [12]. 
3. Current Approaches in Search for EPIs in Gram Positive Bacteria 
The methicillin-resistant Staphylococcus aureus (MRSA) is a major multidrug resistant Gram-positive 
bacteria that is a main cause of healthcare-associated infections (HAIs) resulting in a high death rate. 
MRSA is able to acquire resistance to various antibiotics, including tetracyclines, aminoglycosides and 
flouroquinolones. Studies on MDR efflux mechanisms in S. aureus indicated that NorA is predominant 
protein efflux pump [3]. For these two reasons, NorA in S. aureus is a frequently studied efflux pump 
as well as being the main protein target in the search for efflux pump inhibitors in the case of Gram-
positive bacteria.  
Recent decades have seen the production of a number of new chemical compounds belonging to 
various chemical families, which were investigated on their NorA EPI properties [3,10,26–38,70]. In 
the studies, an examination of the new compounds on their EPI properties have predominantly been 
based on: (1) a comparison of antibiotics efficacy in the presence- to that in the absence of the tested 
compound in the strain over-producing efflux pump and/or (2) the assays of inhibition of a substrate-
efflux, mediated by the efflux pump, at various concentrations of the tested compound. In both types of 
assays, S. aureus SA 1199B was the most often used strain over-producing NorA efflux pump, and the 
wild strain S. aureus SA 1199 was involved as a reference one. Ciprofloxacin (CPX) is described as 
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the most often used antibiotic, and ethidium bromide (EtBr) as the main reference substrate of NorA 
applied in the (real-time) efflux assays. 
3.1. Plant-Derived NorA EPIs and Their Chemical Modifications  
The role of phytochemistry in search for compounds inhibiting NorA of S.aureus is significant as it 
is reported to be an extremely varied series of plant-derived EPIs displaying different chemical 
properties, including flavones, isoflavones, acylated glycosides, porphyrin phaeophorbide A or 
kaempferol rhamnoside [34,70]. 
Chemical structures of the natural EPIs have been a good starting point for further modifications to 
search for new inhibitors with higher potency and better pharmacological profile. In this context, 
Sabatini et al. [34] described the synthesis of a series of 2-(4-propoxyphenyl)quinoline derivatives, that 
was designed on the basis of natural flavones nucleus (Figure 1). The compounds were investigated on 
their EPIs action in the ethidium bromide (EtBr) inhibition assays on strain S. aureus SA-1199B  
over-expressing norA. The most active compounds 25f, 28f, 28j and 29f displayed more than 65% 
inhibition of EtBr at their 50 µm concentration. 
Figure 1. The most active inhibitors of the S. aureus NorA efflux pump among 2-(4-
propoxyphenyl)quinoline [34]. 
Reduction of  EtBr efflux: 75.1% (at 50 M)
Intrinsic antibacterial activity: >256 M
R1, R4= H, Me, -(CH2)2N(Et)2, -(CH2)2-(piperidin-1-yl)
R6, R7= H, OH, OMe
N
O
R6
R7
R1
R4'
N
OR4
R6
R7
R4'
N
O
O
N
25f
R4'= H, OH, On-PrMe, OMe, OEt, Oi-Pr, 
-(CH2)2N(Et)2, -(CH2)2N(Me)2,
 -(CH2)2-(piperidin-1-yl),  -(CH2)2-(morpholin-4-yl)
General structure A General structure B
Reduction of  EtBr efflux: 88.5% (at 50 M)
Intrinsic antibacterial activity: 256 M
Reduction of  EtBr efflux: 65.6% (at 50 M)
Intrinsic antibacterial activity: >223 M
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b) The most active compounds:
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N
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O
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Intrinsic antibacterial activity: >241 M
 
 
(a) General Structures 
(b) The most active compounds  
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Figure 1. Cont. 
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Signatures of compounds according to the source reference [34]. 
Thota et al. [29] described a series of citral derived amides that have been obtained from 
monoterpene citral or citronellal (Figure 2). 
Figure 2. Citral amide derivatives that potentiate MIC of ciprofloxacin on S. aureus 1199. 
The most active compounds found within the assays [29]. MEC value describes minimal 
effective concentration of the tested compounds. 
O
HN
 5
O
N
17
O
N
H
OH
O
26
MEC of EPI = 6.25 g/mL
MEC of EPI = 12.5 g/mL MEC of EPI = 12.5 g/mL
MEC of Reserpine = 25 g/mL
MEC of Carsonic acid = 25 g/mL
MEC of Verapamil = 50 g/mL
MEC of Piperine = 50 g/mL
MEC values for reference compounds:
 
Signatures of compounds according to the source reference [29]. 
The compounds were investigated on their abilities to decrease minimal inhibitory concentration of 
ciprofloxacin in the strains of S. aureus over-producing NorA pump. The EPI-action of the compounds 
was expressed as MEC-value (minimal dose of the tested compound that caused a decrease in the MIC 
of ciprofloxacin). As reference compounds, reserpine, carsonic acid, verapamil and piperine were used. 
The most active compound, 2,6,8-trienoic acid amide derivative 26 improved antimicrobial action of 
ciprofloxacin at the compound concentration 4–8 fold lower than that of reference inhibitors. Dienoic 
acid piperidide derivative (17) and 2,4,8-trienoic derivative of octylamide (5) were active at their doses 
2–4 fold lower than those of reference EPIs (Figure 2) [29]. 
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3.2. Chalcones and Alkenamide Inhibitors of the NorA in S. aureus 
The newest work of Holler et al. [28] focuses on a series of 117 chalcone derivatives modified at 
each position of both phenyl rings (Figure 3a). The compounds were tested on their EPI activity 
against NorA mediated ethidium bromide efflux in real-time efflux assay (RTE) in the strain 
SA1199B. Five active compounds were found. Among them two N,N-dimethylaminoethoxyphenyl 
derivatives 9 and 10 (Figure 3b) were equipotent to reserpine, that was used as reference EPI in the 
studies. The compounds tested at their concentration of 20 µg/mL displayed almost total inhibition of 
EtBr efflux (Figure 3c). 
Figure 3. Chalcone inhibitors of the NorA efflux pump in S. aureus; (a) the general 
structure of the chalcone EPIs; (b) the most active inhibitors found in the real-time efflux 
(RTE) assay; (c) Inhibition of EtBr efflux in SA1199B at compounds concentration of  
20 µg/mL for the most active chalcones 9 and 10 [28]. 
Rn= -H, -OH,  -OCH3, -OCH2CH2N(CH3)2, 
-OCH2COOH, N(CH3)2
n= 1-5, 1'-5'
O
R1'
R2'
R3'
R4'
R5'
R5
R4
R3
R2
R1
O
O O
N
H3C
CH3
O
O N
CH3N
H3C
CH3
CH3
9
10
a) b) 
 
Compound inhibition [%] IC50 (µg) IC50 (µM) 
9 99.1 3.5 9.0 
10 98.7 2.6 7.7 
Reserpine 85.1 5.1 8.2 
Signatures of compounds according to the source reference [28]. 
Michalet et al. [10] performed studies among N-cinnamoylphenalkylamide derivatives with 
(un)substituted phenyl or indole at one terminated fragment and (un)substituted phenyl at the opposite 
terminate fragment (Figure 4a). 
Figure 4. N-cinnamoylphenalkylamide derivatives investigated according to their efflux 
pump inhibitors (EPIs) action in the strain over-producing NorA pump; (a) general structures 
of the N-cinnamoylphenalkylamides; (b) the structure of the most active inhibitor [10]. 
R3, R4, R5 = -H, -OH or -OCH3, 
Ar= Ph, 3,4-dihydroxyphenyl, 
3,4,5-trihydroxyphenyl, indole
H
N
O
R4
R3
a) b)
Ar
R5
H
N
O
OMe
OMeHN
Fold reduction of  norfloxacin MIC
(the tested concentration of the compound):
16 (286 M); 8 (57 M); 4(29 M).  
Signatures of compounds according to the source reference [10]. 
(c) 
(b) 
(a) 
(b) (a) 
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In the case of both aromatic fragments electrodonated substituents were considered. The most active 
compound (Figure 4b), possessing indole moiety and 3,4-dimethoxycinnamoyl fragment, caused a  
4-fold reduction of norfloxacin MIC at the lowest concentration of 29 µM. 
Compounds with similar topology of conjugated double bonds were obtained and investigated by 
Thota et al. [30], who found new EPIs among derivatives of 3,4-dihydronaphth-2-yl-propenoic acid 
(Figure 5). The compounds were examined according to their ability to improve the efficacy of 
ciprofloxacine in MDR strains of S. aureus (1199B and 1199). The most active compounds included 
chemical moieties of isobutylamide (8, 20), diisopropylamide (21) and piperidide (24). The 
compounds were able to reduce MIC of ciprofloxacine (CPX) in 2–16-fold at their concentrations 1–4 
fold lower than those of reference EPI (Figure 5). The simple structure of 3-(3,4-dihydronaphth-2-yl)-
propenoic acid isobutyl amide (20) was the most promising one, which caused a 16-fold reduction of 
MIC of CPX in strain 1199B and 4-fold in the case of 1199 strain. Its MEC value (12.5 µg/mL) was 4-fold 
lower than that of piperine and verapamil and 2-fold lower than that of reserpine and carsonic acid. 
Figure 5. Dihydronaphthalene inhibitors of the NorA efflux pump in S. aureus [30]. (a) 
Structures of the most active compounds (20, 21, 24 and 8); (b) Abilities of the most active 
compounds to potentiate antimicrobial action of ciprofloxacin (CPX) in comparison to 
reference compounds. 
O
HN
20 O
N
21
O
N
24
O
HN
O
O
8  
Compound 
Fold reduction of MIC of CPX MEC of EPI 
(µg/mL) S. aureus 1199B (overproducing NorA) S. aureus 1199 (wild-type) 
8 2 0 12.5 
20 16 4 12.5 
21 16 4 25 
24 8 2 12.5 
Piperine 2 2 50 
Reserpine 4 2 25 
Carsonic acid 2 2 25 
Verapamil 2 2 50 
Signatures of compounds according to the source reference [30]. 
3.3. Piperine EPIs against NorA in S. aureus 
Piperine (Figure 6a) is an alkaloid that was isolated from the fruits of Piper nigrum by H.C. Orsted 
in 1819. This natural compound displays properties of the inhibitors of some proteins important for 
metabolism and xenobiotics transport and it is used as a reference inhibitor in studies on new efflux 
(a) 
(b) 
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pump inhibitors [29,30]. On the basis of the inhibitor properties of piperine, Nargotra et al. [33] 
designed and synthesized a series of piperine analogs, in which piperidine moiety was modified by 
replacement with other amines (Figure 6b). The new compounds were investigated according to their 
ability to reduce MIC of ciprofloxacin in S. aureus 1199B strain using eight different concentrations of 
the investigated compounds (0–50 µg/mL). Potentiation factor (PF) was calculated to express the 
potentiation of activity of ciprofloxacin in the presence of the tested new EPIs, reflected in the reduced 
MIC of combination compared to that of ciprofloxacin alone (Fig 6d). Three of the most promising  
EPIs were found (Figure 6c) in which the piperidine fragment of piperine was replaced with  
3-aminobenzonitrile (13), N-(3-aminophenyl)acetamide (16) or 3-amino-N-phenylbenzamide (20). The 
highest potentiation factor was observed for the benzonitrile amide derivative (13), whereas the  
3-amino-N-phenylbenzamide derivative (20) displayed EPIs activity at the lowest concentration with 
its MEC value of 3.12 µg/mL (Figure 6d).  
Figure 6. Piperine analogs that decrease MIC of ciprofloxacin in MDR S. aureus strain 
over-producing NorA (1199B); (a) structure of piperine; (b) the general structure of the 
tested compounds; (c) the most active compounds 13, 16 and 20; (d) Abilities of 
compounds 13, 16, 20 to increase efficacy of ciprofloxacin [33]. 
R: alkyl, alkylalcohol, aryl-alkylalcohol, 
Ph, benzonitrile, acetanilide, 
benzoilanilide, benzothiazole
O
HN
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O
O
O
NH
O
O
O
HNO
O
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O
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a)
b)
O
NH
O
O
N
H O
20
O
N
O
O piperine
c)
 
 
Comp. 
MIC of 
EPI 
(µg/mL) 
Potentiation 
factor (PF) 
MIC of CFX 
S. aureus 1199B (µg/mL) 
MEC of 
EPI 
(µg/mL) 
Fold 
reduction of 
MIC of CPX Without EPI With EPI 
13 >100 660 8 1 50 8 
16 >100 320 8 2 12.5 4 
20 >100 360 8 4 3.12 2 
Signatures of compounds according to the source reference [33]. 
The series of compounds was used in quantitative structure-activity relationship studies (QSAR) to 
evaluate QSAR parameters that are responsible for NorA EPIs. In the QSAR studies, the authors 
considered seven categories of descriptors as follows: energy-state indices, electronic, information 
content, spatial, structural, thermodynamic and topological ones. On the basis of the obtained QSAR 
(d) 
(c) 
(b) 
(a) 
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model, the descriptors of the partial negative surface area (Jurs-PNSA-1) and area of the molecular 
shadow in the XZ plane (Shadow_XZ) were identified as the most important parameters that 
contributed to the potentiation of EPI activity. An increase of Jurs-PNSA-1 is connected with the 
introduction of a polar group into the structure of a modified EPI, which is able to increase the partial 
negative surface area of the compound. This kind of modifications is postulated to be profitable for 
NorA efflux pump inhibitory properties. Similarly, changes of the placement of substitutuent(s) (ortho- 
meta- or para), which increase Shadow_XZ parameter, are profitable for the activity. Furthermore, the 
parameter of heat of formation (Hf) was demonstrated as a factor important for NorA inhibitory 
properties in S. aureus. 
3.4. Indoles as Inhibitors of the NorA of S. aureus 
Compound INF55, 5-nitro-2-phenyl-1H-indole (Figure7a), was one of the first identified indole 
EPIs that was capable of producing 4-fold increase susceptibility of S. aureus to ciprofloxacin at its 
concentration of 1.5 g/mL.  
Figure 7. Derivatives or 2-aryl-1H-indoles that display NorA MDR inhibitory activity on 
S. aureus strains (K1758, 8325-4 and K2361); (a) lead structure INF55; (b) the general 
structure of the chemical group described by Samosorn et al. [31]; (c) the most active 
compound (8a) identified within the studies [31]; (d) the general structure of the chemical 
group described by Ambrus et al. [26]; (e) the most promising indoles-EPIs (14, 20 and 25) 
identified [26].  
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Signatures of compounds according to the source references [26,31]. 
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3.5. Other Chemical Groups of NorA EPIs 
Brincat et al. [27] identified four novel inhibitors of the NorA efflux pump of S. aureus belonging 
to different chemical groups. Structures of the compounds were discovered on the basis of virtual 
screening that involved FLAP procedure and new methodology using GRID force field descriptors. 
The compounds created within the ligand-based design were evaluated on their NorA EPI properties  
in silico. The structures identified as active in silico were then synthesized and evaluated 
experimentally on their EtBr efflux inhibition in S. aureus strain SA-1199B as well as on their ability 
to potentiate the antibacterial effect of ciprofloxacin. In this group, the bezimidazole derivative AE-
848/42434549 as well as the benzyloxybezylamine derivative AN-465/42885978 (Figure 8) 
demonstrated the highest EPIs properties as both of the compounds significantly inhibited EtBr efflux 
and did not display intrinsic antibacterial activities. Two other compounds, pyridine- and rhodanine 
derivatives (Figure 8), demonstrated significant inhibitory properties but their intrinsic antibacterial 
action was significant as well. 
Figure 8. Four NorA EPIs found by the use of virtual screening and their EPIs potency to 
inhibit EtBr efflux in SA1199B strain [27]. 
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Signatures of compounds according to the source reference [27]. 
3.6. PSSRI-Based EPIs of NorA and MepA in S. aureus 
Phenylpiperidine selective serotonin reuptake inhibitors (PSSRIs) are able to block the function of 
some MDR efflux pumps. Paroxetine (Figure 9a) was one of the first identified PSSRI that inhibits 
both NorA- (MFS family) and MepA (MATE)-efflux pumps. On the basis of this structure, further 
chemical modifications were performed (Figure 9b) to search for new and more potent EPIs [35,37]. 
German et al. [37] obtained interesting results when replaced benzo[d][1,3]dioxole moiety of 
paroxetine with 2-chloro-5-bromo-phenyl fragment (16, Figure 9c) and exchanged the phenoxyl 
fragment (ether linker) into arylidene one (23, Figure 9c). Both compounds (16, 23) displayed an 
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increase of efflux inhibition of NorA comparing to that of paroxetine. A deletion of fluorophenyl 
substituent was also profitable to give selective EPIs properties for MepA (15 and 24, Figure 9c,d).  
Figure 9. Phenylpiperidine selective serotonin reuptake inhibitor (PSSRI)-based EPIs of  
S. aureus. (a) Paroxetine; (b) general structures (A and B) of the investigated piperidine 
derivatives; (c) the most promising EPIs found within the assays (15, 16, 23, 24) and their 
EPIs potency, expressed as IC50 values for inhibition of NorA (SA-K2361) or MepA (SA-
K2886) in comparison to those of paroxetine [35,37]. 
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15 40 <10 
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Paroxetine 15 <10 
Signatures of compounds according to the source reference [37]. 
3.7. Search for Inhibitors of Other Efflux Pumps of Gram-Positive Bacteria  
Although most of the studies on efflux pump inhibitors for MDR Gram-positive bacteria are 
dedicated to NorA in S. aureus, a few lines of evidence are focused on other protein targets as well. Studies 
on MepA-inhibitors were mentioned in previous research [35,37]. Furthermore, Okandeji et al. [38] 
described C-capped dipeptides that inhibited chloramphenicol-specific efflux pumps, cmlR1 and 
cmlR2, in Streptomyces coelicolor, a strain of Gram-positive bacterium that is relative to the human 
pathogen M. tuberculosis. 
  
(d) 
(  
(b) 
(a) 
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4. Conclusions  
An analysis of the results of the search for new efflux pump inhibitors for Gram-positive bacteria 
which have been performed for last decade indicates that almost all efforts are focused on the NorA 
efflux pump in S. aureus. Considering the chemical structures of the NorA EPIs that have been 
identified, it can be observed that the most active agents belong to the families of compounds possessing 
conjugated double bonds, e.g., chalcones, piperine-like compounds, N-cinnamoylphenalkylamides or 
citral amide derivatives. Indole-, dihydronaphthyl-, 2-chloro-5-bromo-phenyl- or piperidine moieties 
seem to be profitable for the EPI properties as well.  
To date, no inhibitors of bacterial efflux pumps have been licensed for use in the treatment of 
bacterial infections in human or veterinary settings, although research continues. As far as Gram-
positive bacteria are concerned, none of the efflux pump inhibitors have entered clinical trials yet [69,71]. 
Nevertheless, in the last decade, studies on MDR Gram-positive EPIs allowed us to identify new active 
agents of NorA in S. aureus with EPI-potency significantly higher than that of reference inhibitors. 
The active compounds give a new hope for their future therapeutic usage as antibiotics “adjuvants” and 
should be a subject of wider investigations, including their pharmacokinetic properties and toxic 
effects. In particular, further studies should be concentrated on the influence of the NorA agents on 
eucariotic efflux- and influx transport proteins with a special consideration of human transporters 
belonging to the ABC or SLC families. As human proteins expelling toxic substances out of tissues 
display significant similarities to those involved in bacterial MDR, bacterial EPIs probably inhibit 
human detoxification simultaneously with the inhibition of bacterial MDR. This aspect requires 
thorough research for each active bacterial EPI that is considered as a future “adjuvant” of antibiotics. 
In contrast to NorA inhibitors, a population of EPIs active against other MDR efflux proteins of 
Gram-positive bacteria, which have been found during the last decade, is very small. These results, 
together with an increasing knowledge about a variety of efflux pumps that are involved in MDR of 
Gram-positive pathogens, seem to be an important challenge for current medicinal chemistry. They 
underline the opinion that, in the future, the search for new EPIs should pay more attention to developing 
MDR efflux protein targets, including SMR, MATE, ABC or other members of the MFS family. 
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